This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Johnson & Johnson’s Top Scientist to Depart
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Johnson & Johnson’s Top Scientist to Depart
Business

Johnson & Johnson’s Top Scientist to Depart

Editorial Board Published October 12, 2021
Share
Johnson & Johnson’s Top Scientist to Depart
SHARE

Johnson & Johnson’s JNJ -0.42% top scientist, who oversaw a turnaround in the company’s pharmaceutical unit and the development of a Covid-19 vaccine, will retire at the end of the year.

Contents
Newsletter Sign-upCoronavirus Briefing and Health Weekly

Paul Stoffels, who is 59 years old, will step down Dec. 31 as vice chairman of the executive committee and chief scientific officer, J&J said Tuesday.

The New Brunswick, N.J., company, which makes Band-Aid bandages and Tylenol pain reliever as well as therapies for diseases like cancer and psoriasis, didn’t immediately name a replacement.

“As a physician and a scientist, it is gratifying to see the healthcare landscape transformed as we unlock the best science and technology to deliver innovative medicines to solve the world’s toughest health challenges,” Dr. Stoffels said.

This is the second departure of a senior executive that J&J has disclosed in recent weeks. In August, the company said Alex Gorsky will retire as chief executive and serve as executive chairman, effective Jan. 3, 2022.


Newsletter Sign-up

Coronavirus Briefing and Health Weekly

Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.


J&J named longtime executive Joaquin Duato to succeed Mr. Gorsky as CEO.

Dr. Stoffels is retiring to spend more time with his family in Europe and to cut down on travel, according to a person familiar with the matter. He frequently flew back and forth between the U.S. and Europe for his J&J job duties.

Dr. Stoffels began his career as a physician in Africa focusing on tropical-disease research before joining J&J’s Janssen Pharmaceutica division in Belgium, his first stint at J&J.

In the early 1990s, he left J&J to co-found companies that would become Tibotec-Virco, a Belgian developer of antiviral drugs.

Dr. Stoffels rejoined J&J when it acquired Tibotec-Virco in 2002 and helped lead the big company’s development of HIV drugs. J&J is now a leading seller of the medicines, which have helped turn infections into a manageable condition.

He became J&J’s global head of pharmaceutical research and development at J&J in 2009 and later served as chairman of the pharmaceutical unit for several years. He has served as J&J’s chief scientific officer of J&J since 2012.

Since Dr. Stoffels took over pharmaceutical R&D in 2009, the company’s annual pharmaceutical revenue has doubled to $45.6 billion in 2020, making J&J a dominant force in the industry.

The company has made successful bets on new drugs for cancer, such as Darzalex and Zytiga, while expanding offerings for immune-mediated conditions like psoriasis.

Under Dr. Stoffels’ leadership, J&J said, its pharmaceutical R&D teams developed more than 25 new medicines, seven of which have been added to the World Health Organization’s list of essential medicines.

Dr. Stoffels pushed J&J to pursue medicines for the developing world, including one for multidrug-resistant tuberculosis and vaccines against Ebola and Covid-19.

“With Paul at the helm, Janssen rejuvenated its pipeline, launching multiple new medicines, making a difference for people all over the world,” Mr. Duato said in a press release.

Beginning in early 2020, Dr. Stoffels oversaw the development of a Covid-19 vaccine and was often the public face providing updates on J&J’s progress. The vaccine proved generally safe and effective in a large clinical trial and was authorized for use in the U.S. this past February.

Uptake of the J&J Covid-19 vaccine, however, has been less than expected because of safety concerns surrounding a rare blood-clot condition seen in some vaccine recipients as well as manufacturing problems that limited the dose supply.

Write to Peter Loftus at peter.loftus@wsj.com

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article DoorDash Introduces Search-Page Ads for Restaurants DoorDash Introduces Search-Page Ads for Restaurants
Next Article House Set to Temporarily Raise Debt Limit House Set to Temporarily Raise Debt Limit

Editor's Pick

JPMorgan unveils its 2025 summer season studying record

JPMorgan unveils its 2025 summer season studying record

JPMorgan Chase Chairman and CEO Jamie Dimon on the significance of management abilities, deregulation coverage, power independence and the Federal…

By Editorial Board 4 Min Read
2025 Summer time Guide Information: Discover your seashore reads right here
2025 Summer time Guide Information: Discover your seashore reads right here

Story first appeared in: Has studying books ever appeared extra important than…

23 Min Read
Man shot and killed on one hundredth Avenue in Oakland on Saturday
Man shot and killed on one hundredth Avenue in Oakland on Saturday

Oakland police are investigating the loss of life of a person, 34,…

1 Min Read

Oponion

24 Thrifted Fall Items: Tales of Classic Treasures & Handcrafted Wool | Fashion

24 Thrifted Fall Items: Tales of Classic Treasures & Handcrafted Wool | Fashion

We independently consider all advisable services and products. Any services…

December 19, 2024

How Good Agriculture Can Make the most of a Satellite tv for pc API for Earth Commentary

The agricultural sector is present process…

May 21, 2025

Tiffany Trump Pregnant: Her Motherhood Journey With Husband Michael Boulos Defined

Studying Time: 3 minutes As anticipated,…

January 21, 2025

Amy Slaton Pregnant? 1000-Lb. Sisters Star Responds!

We now have an replace on…

November 5, 2024

26 Finest Buzz Lower Haircuts for Males: Final Information in 2025 | Fashion

We independently consider all beneficial services.…

January 30, 2025

You Might Also Like

3 Modern Methods Healthcare Companies Use Tech To Enhance The Affected person Expertise
Business

3 Modern Methods Healthcare Companies Use Tech To Enhance The Affected person Expertise

The healthcare trade is among the largest proponents of know-how use all through the office. It’s an trade stuffed with…

4 Min Read
Environment friendly and environmentally pleasant video doorbell power answer: YMIN supercapacitor
Business

Environment friendly and environmentally pleasant video doorbell power answer: YMIN supercapacitor

01 Supercapacitors Changing Batteries: Advancing Good Video Doorbells with Environment friendly Energy Provide With the rising adoption of good residence…

4 Min Read
High programming languages to make use of to your IoT mission
Business

High programming languages to make use of to your IoT mission

What’s the neatest technique to construct a linked product with out losing time on the fallacious tech? Selecting the most…

10 Min Read
GCT Semiconductor and Giesecke+Devrient Companion to Launch Modern eSIM Answer for IoT Gadgets
Business

GCT Semiconductor and Giesecke+Devrient Companion to Launch Modern eSIM Answer for IoT Gadgets

GCT Semiconductor Holding Inc., a number one designer and provider of superior 4G and 5G semiconductor options, and Giesecke+Devrient (G+D),…

3 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?